403 related articles for article (PubMed ID: 11155821)
21. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
[TBL] [Abstract][Full Text] [Related]
22. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
[TBL] [Abstract][Full Text] [Related]
23. Vaccination with allogeneic GM-CSF gene-modified lung cancer cells: antitumor activity comparing with that induced by autologous vaccine.
Li H; Jiang HJ; Ma MQ; Wei F; An XM; Ren XB
Cancer Biother Radiopharm; 2007 Dec; 22(6):790-8. PubMed ID: 18158770
[TBL] [Abstract][Full Text] [Related]
24. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
Shao Y; Sun X; He Y; Liu C; Liu H
PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
[TBL] [Abstract][Full Text] [Related]
25. Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results.
Dols A; Smith JW; Meijer SL; Fox BA; Hu HM; Walker E; Rosenheim S; Moudgil T; Doran T; Wood W; Seligman M; Alvord WG; Schoof D; Urba WJ
Hum Gene Ther; 2003 Jul; 14(11):1117-23. PubMed ID: 12885350
[TBL] [Abstract][Full Text] [Related]
26. The role of TPS, CA125, CA15-3 and CEA in prediction of distant metastasis of breast cancer.
Zhang J; Wei Q; Dong D; Ren L
Clin Chim Acta; 2021 Dec; 523():19-25. PubMed ID: 34454906
[TBL] [Abstract][Full Text] [Related]
27. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.
Murray JL; Gillogly ME; Przepiorka D; Brewer H; Ibrahim NK; Booser DJ; Hortobagyi GN; Kudelka AP; Grabstein KH; Cheever MA; Ioannides CG
Clin Cancer Res; 2002 Nov; 8(11):3407-18. PubMed ID: 12429628
[TBL] [Abstract][Full Text] [Related]
28. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
[TBL] [Abstract][Full Text] [Related]
29. Comparison of serum CA15-3 and CEA in breast cancer.
Hou MF; Huang TJ; Hsieh JS; Huang YS; Huang CJ; Chan HM; Wang JY; Chen YL; Jong SB; Yang CC
Gaoxiong Yi Xue Ke Xue Za Zhi; 1995 Dec; 11(12):660-6. PubMed ID: 8551526
[TBL] [Abstract][Full Text] [Related]
30. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
Gulley JL; Arlen PM; Tsang KY; Yokokawa J; Palena C; Poole DJ; Remondo C; Cereda V; Jones JL; Pazdur MP; Higgins JP; Hodge JW; Steinberg SM; Kotz H; Dahut WL; Schlom J
Clin Cancer Res; 2008 May; 14(10):3060-9. PubMed ID: 18483372
[TBL] [Abstract][Full Text] [Related]
31. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.
Norell H; Poschke I; Charo J; Wei WZ; Erskine C; Piechocki MP; Knutson KL; Bergh J; Lidbrink E; Kiessling R
J Transl Med; 2010 Jun; 8():53. PubMed ID: 20529245
[TBL] [Abstract][Full Text] [Related]
32. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.
Hayes DF; Zurawski VR; Kufe DW
J Clin Oncol; 1986 Oct; 4(10):1542-50. PubMed ID: 2428949
[TBL] [Abstract][Full Text] [Related]
33. Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer.
Nicolini A; Rossi G; Ferrari P; Carpi A
Biomed Pharmacother; 2014 Mar; 68(2):171-8. PubMed ID: 24491318
[TBL] [Abstract][Full Text] [Related]
34. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
Grosenbach DW; Barrientos JC; Schlom J; Hodge JW
Cancer Res; 2001 Jun; 61(11):4497-505. PubMed ID: 11389081
[TBL] [Abstract][Full Text] [Related]
35. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
36. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor.
Ullenhag GJ; Frödin JE; Jeddi-Tehrani M; Lidströmer N; Strigård K; Eriksson E; Samanci A; Choudhury A; Nilsson B; Rossmann ED; Mosolits S; Mellstedt H
Clin Cancer Res; 2004 May; 10(10):3273-81. PubMed ID: 15161680
[TBL] [Abstract][Full Text] [Related]
37. Combining the tumor abnormal protein test with tests for carcinoembryonic antigens, cancer antigen 15-3, and/or cancer antigen 125 significantly increased their diagnostic sensitivity for breast cancer.
Chen R; Jiang C; Zhu Q; You S; Li Y; Li S; Ding L; Meng H; Yang Y; Zha X; Wang J
Medicine (Baltimore); 2020 Jul; 99(29):e21231. PubMed ID: 32702897
[TBL] [Abstract][Full Text] [Related]
38. Leukocyte alkaline phosphatase, CA15-3, CA125, and CEA in cancer patients.
Walach N; Gur Y
Tumori; 1998; 84(3):360-3. PubMed ID: 9678617
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
40. Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125.
Wagner U; Schlebusch H; Köhler S; Schmolling J; Grünn U; Krebs D
Hybridoma; 1997 Feb; 16(1):33-40. PubMed ID: 9085126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]